2,6-dimethyl-4-(piperidin-4-yl)morpholine | 551923-15-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 2,6-dimethyl-4-(piperidin-4-yl)morpholine
• 英文别名: 2,6-Dimethyl-4-piperidin-4-yl-morpholine；2,6-dimethyl-4-piperidin-4-ylmorpholine
• CAS: 551923-15-0
• 化学式: C₁₁H₂₂N₂O
• mdl: MFCD03274732
• 分子量: 198.308
• InChiKey: MYYJFAYHVMWIDI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  24.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2,6-dimethyl-4-(piperidin-4-yl)morpholine 在 potassium carbonate 、 氯化铵 、 对甲苯磺酸 作用下， 以 四氢呋喃 、 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 11.17h， 生成 5-chloro-2-N-[4-[4-(2,6-dimethylmorpholin-4-yl)piperidin-1-yl]-2-methoxyphenyl]-4-N-(2-propan-2-ylsulfonylpyridin-3-yl)pyrimidine-2,4-diamine
  参考文献：
  名称：

  PYRIMIDINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF CANCER

  摘要：

  公开号：

  EP3372594B1

文献信息

• [EN] PYRIMIDO [5,4-D] PYRIMIDINE DERIVATIVES FOR THE INHIBITION OF TYROSINE KINASES<br/>[FR] DÉRIVÉS PYRIMIDO-[5,4-D]-PYRIMIDINE POUR L'INHIBITION DES TYROSINE-KINASES
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2010094695A1

  公开（公告）日：2010-08-26

  The present invention encompasses compounds of general formula (1), wherein the groups R1 to R4, X1, X2, X3, X4, X5, Q, L1 and L2 are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, as well as pharmaceutical preparations and formulations of these compounds.

  本发明涵盖了一般式（1）的化合物，其中基团R1至R4、X1、X2、X3、X4、X5、Q、L1和L2的定义如权利要求书中所述，这些化合物适用于治疗以细胞过度增殖或异常增殖为特征的疾病，以及这些化合物的药物制剂和配方。
• PYRIDO [5, 4-D] PYRIMIDINES AS CELL PROLIFERATION INHIBITORS
  申请人：Mantoulidis Andreas

  公开号：US20120094975A1

  公开（公告）日：2012-04-19

  The present invention encompasses compounds of general formula (1) wherein the groups R 1 to R 4 , X 1 , X 1 , X 3 , L 1 and L 2 are defined as in claim 1 , which are suitable for the treatment of diseases characterised by excessive or anomalous cell pro-liferation, and the use thereof in such a treatment.

  本发明涵盖了一般式（1）中的化合物，其中基团R1至R4、X1、X1、X3、L1和L2如权利要求1中定义的那样，适用于治疗以细胞过度或异常增殖为特征的疾病，并且在此类治疗中的使用。
• PYRIMIDO [5,4-D] PYRIMIDINE DERIVATIVES FOR THE INHIBITION OF TYROSINE KINASES
  申请人：Ettmayer Peter

  公开号：US20120046270A1

  公开（公告）日：2012-02-23

  The present invention encompasses compounds of general formula (1), wherein the groups R 1 to R 4 , X 1 , X 2 , X 3 , X 4 , X 5 , Q, L 1 and L 2 are defined as in claim 1 , which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, as well as pharmaceutical preparations and formulations of these compounds.

  本发明涵盖了通式（1）的化合物，其中R1到R4，X1，X2，X3，X4，X5，Q，L1和L2的基团如权利要求1中所定义，这些化合物适用于治疗由细胞过度增殖或异常增殖所特征的疾病，以及这些化合物的制药制剂和配方。
• 6-morpholinyl-2-pyrazolyl-9H-purine derivatives and their use as PI3K inhibitors
  申请人：Daiichi Sankyo Company, Limited

  公开号：US10174035B2

  公开（公告）日：2019-01-08

  The present invention relates to a pyrazole derivative of formula (I), a pharmaceutically acceptable salt thereof, a prodrug thereof, a hydrate thereof, stereoisomer thereof or a deuterium form thereof, wherein, n, Y, Ra, R1, R2, R3, R4, R5 and R6 are as defined hereinafter in the specification, a pharmaceutical composition comprising a compound of formula (I) as an active ingredient, methods of production, and methods of use thereof. Particularly, the present invention provides a compound of formula (I) as inhibitors of phosphatidylinositol-3-kinase (PI3K), which can be used for treating or preventing inflammatory, autoimmune, orphan and hyperproliferative disease and disorder.

  本发明涉及一种式（I）的吡唑衍生物、其药学上可接受的盐、其原药、其水合物、其立体异构体或其氘代形式，其中，n、Y、Ra、R1、R2、R3、R4、R5 和 R6 如下文说明书中所定义；一种包含式（I）化合物作为活性成分的药物组合物、其生产方法和使用方法。 特别是，本发明提供了作为磷脂酰肌醇-3-激酶（PI3K）抑制剂的式(I)化合物，可用于治疗或预防炎症性、自身免疫性、孤儿和过度增殖性疾病和紊乱。
• Pyrimidine derivative and use thereof
  申请人：Hubei Bio-Pharmaceutical Industrial Technological Institute Inc.

  公开号：US10695347B2

  公开（公告）日：2020-06-30

  The present invention provides a pyrimidine derivative and a use thereof. The pyrimidine derivative is the compound shown in formula I or a pharmaceutically acceptable salt, hydrate, solvate, metabolite or prodrug thereof, wherein, R1, R2, R3, R4 and R5 are, for example, as defined in the specification. The compound can act as an ALK inhibitor, and is for preparing an anti-tumor medicament for suppressing an anaplastic lymphoma kinase.

  本发明提供了一种嘧啶衍生物及其用途。嘧啶衍生物是式 I 所示的化合物或其药学上可接受的盐、水合物、溶液、代谢物或原药，其中，R1、R2、R3、R4 和 R5 例如如说明书中所定义。该化合物可作为 ALK 抑制剂，用于制备抑制无性淋巴瘤激酶的抗肿瘤药物。